Australia - English - Department of Health (Therapeutic Goods Administration)

meglumine diatrizoate; sodium diatrizoate -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 aug 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: pentetate meglumine; meglumine; water for injections - indications as at 30 aug 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: meglumine; pentetate meglumine; water for injections - indications as 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

New Zealand - English - Medsafe (Medicines Safety Authority)

covidien nz ltd - meglumine amidotrizoate 66%; sodium amidotrizoate 10%;   - solution for injection - active: meglumine amidotrizoate 66% sodium amidotrizoate 10%   excipient: disodium edetate dihydrate sodium citrate dihydrate sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

obex medical ltd - meglumine amidotrizoate 66%{relative};  ; sodium amidotrizoate 10%{relative};   - oral solution - active: meglumine amidotrizoate 66%{relative}   sodium amidotrizoate 10%{relative}  

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine amidotrizoate 0.18 g/ml; sodium amidotrizoate 0.4 g/ml - solution for injection - 0.18g,0.4g/ml - active: meglumine amidotrizoate 0.18 g/ml sodium amidotrizoate 0.4 g/ml